Phosphoinositide biosynthetic pathway (PI/PIP pathway)

The phosphoinositide biosynthetic pathway is a fundamental metabolic and signaling network that generates phosphatidylinositol (PI) and its phosphorylated derivatives, known as phosphoinositides (PIPs) (Wikipedia, 2024; Cell Signaling Technology, 2020). These lipids are vital for maintaining membrane integrity and regulating key cellular processes such as signal transduction, vesicle trafficking, and actin cytoskeleton dynamics (NIH, 2021; MDPI, 2023). The pathway involves a complex interplay of lipid kinases (e.g., PI3K, PI4K) and phosphatases (e.g., PTEN) that interconvert PIP species to create localized signaling hubs (Frontiers, 2023; NIH, 2025). Dysregulation of this pathway, particularly the PI3K/AKT/mTOR axis, is a major driver in many cancers, leading to enhanced cell survival and proliferation (BOC Sciences, 2024; ResearchGate, 2021). Furthermore, the pathway is a target in psychiatry, where lithium inhibits inositol monophosphatase to modulate signaling in bipolar disorder (ResearchGate, 2008). Therapeutic strategies focus on inhibiting specific enzymes within the pathway to treat oncology, inflammatory, and metabolic diseases (NIH, 2021).

Other names

Phosphatidylinositol biosynthetic pathwayPhosphoinositide signaling pathwayPI3K/AKT pathwayInositol phosphate metabolismPI metabolism

Inhibition of lipid kinases (e.g., PI3K, PI4K) and phosphatases, or depletion of inositol precursors to disrupt downstream signaling cascades.